诺和诺德因Victoza仿制药上市延迟面临集体诉讼

Core Viewpoint - Novo Nordisk (NVO) experienced a 1.9% decline in stock price due to a collective lawsuit regarding the delayed market entry of its Victoza generic drug [1] Group 1: Lawsuit Details - JM Smith Company accuses Novo Nordisk of acquiring Teva Pharmaceuticals to postpone the launch of its Victoza generic drug until June 2024 [1] - The lawsuit claims that Novo Nordisk manipulated regulatory processes to prevent the FDA from approving any potential competitors for the Victoza generic drug [1] - The lawsuit seeks relief under Section 2 of the Sherman Act on behalf of direct purchasers [1]